Latest Cambridge Antibody Technology Stories
BURLINGAME, Calif., June 12, 2012 /PRNewswire/ -- Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding. The financing round was led by new investor Third Rock Ventures, with participation from existing investors The Column Group, Orbimed Advisors and 5AM Ventures. The closing of the Series C financing increases the total raised by the...
LA JOLLA, Calif., May 31, 2012 /PRNewswire/ -- Scripps Research Institute Professor Richard A. Lerner, MD, has won a prestigious international honor, the Prince of Asturias Award for Scientific and Technical Research, according to an announcement made today by the Prince of Asturias Foundation. Lerner shares the award with British biochemist Sir Gregory Winter, PhD. Sometimes called the "Spanish Nobel Prize," the Prince of Asturias Award for Scientific and Technical Research is...
MARTINSRIED and MUNICH, Germany, and MONROVIA, Calif., May 22, 2012 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208. MOR208 (formerly XmAb®5574) is a potent anti-CD19 antibody with a proprietary modification to the Fc portion, that is being developed to treat B-cell malignancies. A total of 30 patients with relapsed or...
LUXEMBOURG, May 3, 2012 /PRNewswire/ -- Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, announces today that Dr Simon Russell has been appointed as Chief Business Officer. Dr Russell joins Creabilis from Novartis Pharma AG where he held a number global strategic marketing roles and most recently Head of Global Marketing for ILARIS (canakinumab). He was previously Head of Strategic...
SAN DIEGO, May 1, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced an antibody discovery partnership with Gilead Sciences, Inc. to develop novel antibody therapeutics. (Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO) Under this partnership, antibodies generated by AnaptysBio using its proprietary SHM-XEL platform will be transferred to Gilead for worldwide development and commercialization. Gilead has paid an...
MONROVIA, Calif., April 19, 2012 /PRNewswire/ -- Xencor, Inc. announced today that the Company received a milestone payment under an antibody optimization collaboration agreement with CSL Limited. The payment was triggered by filing of an investigational new drug application with the FDA for a novel monoclonal antibody that was optimized using Xencor's XmAb® antibody engineering technology. This is the first XmAb candidate to move into human clinical testing under the agreement...
MONROVIA, Calif., April 4, 2012 /PRNewswire/ -- Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim. The payment was triggered by a regulatory submission to begin Phase 1 clinical trials of a novel monoclonal antibody that was optimized using Xencor's XmAb® antibody engineering technology. This is the second XmAb candidate entering human clinical trials under the agreement with Boehringer...
The Mount Sinai Medical Center and MRC Technology (MRCT), the technology transfer organization for the United Kingdom’s prestigious Medical Research Council, have reached an agreement to collaborate on the development of monoclonal antibodies that can be commercialized as drugs to control infection and treat diseases. New York (PRWEB) April 02, 2012 The Mount Sinai Medical Center and MRC Technology (MRCT), the technology transfer organization for the United Kingdom’s prestigious...
THOUSAND OAKS, Calif. and LONDON, April 2, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)). The companies believe all the molecules have novel profiles and offer the potential to deliver important treatments across multiple indications in inflammatory diseases. The...
SAN DIEGO, March 15, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of David L. Lacey, M.D. and Michael Gallatin, Ph.D. to the company's Therapeutic Advisory Board (TAB). Drs. Lacey and Gallatin will join two founding members of AnaptysBio's TAB, Jan de Vries, Ph.D. and Nicholas B. Lydon, Ph.D. (Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO) AnaptysBio's TAB is constituted to oversee the...
